CORDIS
EU research results

CORDIS

English EN

EURopean Endeavour for Chimeric Antigen Receptor Therapies

Project information

Grant agreement ID: 733297

Status

Ongoing project

  • Start date

    1 January 2017

  • End date

    31 December 2020

Funded under:

H2020-EU.3.1.3.

  • Overall budget:

    € 5 903 146

  • EU contribution

    € 5 903 146

Coordinated by:

MOLECULAR MEDICINE SPA

Italy

Objective

Cancer is rapidly becoming the most frequent cause of death in EU. Though enormously expensive (several billions EUR/year), currently available anti-cancer therapies are major causes of chronic diseases. Adoptive immunotherapy with T cells genetically modified with a tumour-reactive chimeric antigen receptor (CAR) is an innovative therapeutic concept, promising to eradicate cancer without causing secondary chronic diseases. This approach is already at an advanced stage of development in the US, but struggles in the EU, due to a number of constrains that will be specifically tackled by this Project. The ultimate goal of EURE-CART is to bring EU at the forefront CAR T-cell immunotherapy. In this Project, we will extend the applicability of CAR T-cell immunotherapy to incurable tumours that have never been tackled with this approach. The EURE-CART Consortium is composed of 6 academic centres, 2 SMEs and 1 large enterprise from 6 EU countries, clearly representing excellences in their respective fields. EURE-CART will bring together clinical experts in oncology, and pioneers and leaders in the field of cell and gene therapy for conducting a first-in-man Phase I/II clinical trial. To be successful, EURE-CART proposes the early involvement of National regulatory authorities for accelerating the approval of CAR T-cell immunotherapy, as well as the centralisation of its production by the Molmed Spa. Molmed Spa is uniquely endowed in the EU with the know-how and experience necessary to meet this ambitious objective, as demonstrated by its unparalleled track record. The main expected impact of EURE-CART is the establishment of CAR T-cell therapy as the ultimate personalised therapy, capable of defeating chronic diseases, and to create secure new jobs in the EU through the instalment of an unprecedented alliance between academia, industry and regulatory bodies.

Coordinator

MOLECULAR MEDICINE SPA

Address

Via Olgettina 58
20132 Milano

Italy

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU Contribution

€ 1 994 575

Participants (8)

OSPEDALE SAN RAFFAELE SRL

Italy

EU Contribution

€ 1 112 500

UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT

Germany

EU Contribution

€ 856 076,25

OSPEDALE PEDIATRICO BAMBINO GESU

Italy

EU Contribution

€ 492 431,25

FUNDACIO PRIVADA INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU

Spain

EU Contribution

€ 225 011

FAKULTNI NEMOCNICE OSTRAVA

Czechia

EU Contribution

€ 224 552,50

ISTITUTO SUPERIORE DI SANITA

Italy

EU Contribution

€ 225 000

ACROMION GMBH

Germany

EU Contribution

€ 398 000

ARTTIC

France

EU Contribution

€ 375 000

Project information

Grant agreement ID: 733297

Status

Ongoing project

  • Start date

    1 January 2017

  • End date

    31 December 2020

Funded under:

H2020-EU.3.1.3.

  • Overall budget:

    € 5 903 146

  • EU contribution

    € 5 903 146

Coordinated by:

MOLECULAR MEDICINE SPA

Italy